Sigal S L, Gellman J, Sarembock I J, LaVeau P J, Chen Q S, Cabin H S, Ezekowitz M D
Department of Medicine, Yale University School of Medicine/West Haven VA Medical Center, New Haven, Conn.
Arterioscler Thromb. 1991 May-Jun;11(3):770-83. doi: 10.1161/01.atv.11.3.770.
Vasospasm occurs both in patients and animal models after angioplasty and may be associated with early closure of the dilated vessel. To investigate the mechanism of angioplasty-induced vasospasm, the effect of serotonin-receptor blockade with two serotonin2 (S2) antagonists, LY53857 and sergolexole, was examined in rabbits with focal femoral artery atherosclerosis. In preliminary studies, local infusion of 1-100 micrograms serotonin caused significant femoral artery vasoconstriction (p less than 0.05) in both normal and atherosclerotic rabbits. There was no significant difference in the degree of vasoconstriction induced by equal doses of serotonin in normal and atherosclerotic animals. Infusion of 10 micrograms serotonin produced a 23 +/- 5% decrease in luminal diameter in atherosclerotic femoral arteries. This was blocked by pretreatment with both S2 inhibitors given separately in different animals before serotonin infusion (p less than 0.002). In contrast, LY53857 (sergolexole was not tested) had no significant effect on phenylephrine-induced vasoconstriction, confirming its specificity as an S2-receptor antagonist. Balloon angioplasty of atherosclerotic vessels caused a significant increase in vessel diameter at the angioplasty site (45% increase from baseline diameter, p less than 0.05). This was associated with significant luminal narrowing both proximal (21% reduction from baseline, p less than 0.05) and distal (17% reduction from baseline, p less than 0.03) to the angioplasty site. These proximal and distal changes are most likely due to vasospasm, as there was no histological evidence of thrombus or dissection at these sites to explain the luminal narrowing. Pretreatment of animals with 10 mg LY53857 or 20 mg sergolexole blocked the proximal vasospasm (2.6 +/- 0.4 before versus 2.2 +/- 0.1mm after angioplasty for LY53857, 2.1 +/- 0.4 before versus 2.1 +/- 0.4 mm after angioplasty for sergolexole; p = NS). Treatment with 20 mg LY53857 inhibited both proximal (2.3 +/- 0.1 before versus 2.2 +/- 0.2 mm after angioplasty, p = NS) and distal (1.7 +/- 0.1 before versus 1.6 +/- 0.2 mm after angioplasty, p = NS) vasospasm after angioplasty. Proximal (2.3 +/- 0.5 before versus 2.5 +/- 0.3 mm after) and distal (1.7 +/- 0.2 before versus 1.7 +/- 0.4 mm after) vasospasm was also prevented by pretreatment with 40 mg sergolexole.(ABSTRACT TRUNCATED AT 400 WORDS)
血管成形术后,患者和动物模型中均会发生血管痉挛,且可能与扩张血管的早期闭合有关。为研究血管成形术诱发血管痉挛的机制,在患有局灶性股动脉粥样硬化的兔子中,检测了两种5-羟色胺2(S2)拮抗剂LY53857和舍吲哚对5-羟色胺受体的阻断作用。在初步研究中,局部输注1-100微克5-羟色胺可使正常和动脉粥样硬化兔子的股动脉显著收缩(p<0.05)。正常和动脉粥样硬化动物中,等量5-羟色胺诱发的血管收缩程度无显著差异。输注10微克5-羟色胺可使动脉粥样硬化股动脉的管腔直径减少23±5%。在不同动物中,5-羟色胺输注前分别用两种S2抑制剂预处理可阻断这种作用(p<0.002)。相比之下,LY53857(未检测舍吲哚)对去氧肾上腺素诱发的血管收缩无显著影响,证实其作为S2受体拮抗剂的特异性。动脉粥样硬化血管的球囊血管成形术可使血管成形部位的血管直径显著增加(较基线直径增加45%,p<0.05)。这与血管成形部位近端(较基线减少21%,p<0.05)和远端(较基线减少17%,p<0.03)的显著管腔狭窄有关。这些近端和远端变化很可能是由于血管痉挛,因为这些部位没有血栓或夹层的组织学证据来解释管腔狭窄。用10毫克LY53857或20毫克舍吲哚预处理动物可阻断近端血管痉挛(LY53857组血管成形术前为2.6±0.4毫米,术后为2.2±0.1毫米;舍吲哚组血管成形术前为2.1±0.4毫米,术后为2.1±0.4毫米;p=无显著性差异)。用20毫克LY53857治疗可抑制血管成形术后的近端(血管成形术前为2.3±0.1毫米,术后为2.2±0.2毫米,p=无显著性差异)和远端(血管成形术前为1.7±0.1毫米,术后为1.6±0.2毫米,p=无显著性差异)血管痉挛。用40毫克舍吲哚预处理也可预防近端(血管成形术前为2.3±0.5毫米,术后为2.5±0.3毫米)和远端(血管成形术前为1.7±0.2毫米,术后为1.7±0.4毫米)血管痉挛。(摘要截断于400字)